NCT04302220

Brief Summary

This study intends to establish a registry cohort to enroll patients with high myopia to study the natural course of myopic optic neuropathy in Chinese adult population.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
813

participants targeted

Target at P75+ for all trials

Timeline
1mo left

Started Jun 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress99%
Jun 2019Jun 2026

Study Start

First participant enrolled

June 6, 2019

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

March 7, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 10, 2020

Completed
6.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2026

Last Updated

December 9, 2024

Status Verified

December 1, 2024

Enrollment Period

7.1 years

First QC Date

March 7, 2020

Last Update Submit

December 6, 2024

Conditions

Keywords

myopic optic neuropathyhigh myopiaglaucoma

Outcome Measures

Primary Outcomes (1)

  • Progression of glaucoma within 36 months

    Structural and functional changes of glaucoma using visual field, stereoscopic fundus photography.

    3 years

Secondary Outcomes (1)

  • Progression of myopia and other structural changes of retina and choroid.

    3 years

Study Arms (1)

high myopia

Population who have high myopia.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who have high myopia aged from 18 to above.

You may qualify if:

  • Age ≥18 years
  • Equivalent spherical ≤-6D or axial length ≥26.5mm
  • Best corrected visual acuity ≥ 6/12

You may not qualify if:

  • Unwilling or unable to give consent, or unable to return for scheduled protocol visits.
  • Glaucoma secondary to penetrating keratoplasty, trauma, steroids, retinal disease/surgery, or neovascular disease.
  • Obvious corneal and iris lesions, or severe cataracts interfering with fundus examinations, VF test or monophthalmia.
  • Need for ocular surgery/laser or anticipated need for cataract surgery during the study period.
  • Other serious systemic diseasesf (i.e. hypertension, heart disease, diabetes, or rheumatic immune system diseases);
  • Pregnant or nursing women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhongshan Ophthalmic Center

Guangzhou, Guangdong, 510000, China

Location

Related Publications (2)

  • Lin F, Chen S, Song Y, Li F, Wang W, Zhao Z, Gao X, Wang P, Jin L, Liu Y, Chen M, Liang X, Yang B, Ning G, Cheng CY, Healey PR, Park KH, Zangwill LM, Aung T, Ohno-Matsui K, Jonas JB, Weinreb RN, Zhang X; Glaucoma Suspects with High Myopia Study Group. Classification of Visual Field Abnormalities in Highly Myopic Eyes without Pathologic Change. Ophthalmology. 2022 Jul;129(7):803-812. doi: 10.1016/j.ophtha.2022.03.001. Epub 2022 Mar 12.

  • Song Y, Wang W, Lin F, Chen S, Jin L, Li F, Gao K, Cheng W, Xiong J, Zhou R, Chen M, Liang J, Zhang J, Jonas JB, Zhang X. Natural history of glaucomatous optic neuropathy in highly myopic Chinese: study protocol for a registry cohort study. BMJ Open. 2020 Dec 30;10(12):e039183. doi: 10.1136/bmjopen-2020-039183.

Biospecimen

Retention: SAMPLES WITH DNA

Saliva smple.

MeSH Terms

Conditions

Eye DiseasesGlaucoma

Condition Hierarchy (Ancestors)

Ocular Hypertension

Study Officials

  • Xiulan Zhang, MD, PhD

    Zhongshan Ophthalmic Center, Sun Yat-sen University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
3 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Ophthalmology, Director of Clinical Research Center, Director of CFDA-certified Pharmaceutical Research Unit, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center

Study Record Dates

First Submitted

March 7, 2020

First Posted

March 10, 2020

Study Start

June 6, 2019

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

June 30, 2026

Last Updated

December 9, 2024

Record last verified: 2024-12

Locations